| Patient | Edward W. Brooke |
|---|---|
| Date of birth | 1942-10-26 |
| Identifiers | MRN HR-ML014-SYN; SSN (made up) 000-14-5063 |
| Document date | 2026-10-13 |
| Author | Howard Bellamy, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subsequent annual wellness visit; no new complaints. [S]
Mr. Brooke is an 83-year-old man with right breast cancer, stage IIA and hormone receptor-positive, treated by bilateral mastectomy and right axillary dissection about a year ago, who has taken tamoxifen 20 mg daily for eleven and a half months. He returns for his subsequent annual wellness visit, two months after his survivorship visit, and completed the health risk assessment beforehand. He has missed no tamoxifen doses. Hot flashes are mild and occur two or three times a week; libido is lower but he is not troubled by it. He has had no leg swelling or pain, chest pain, breathlessness, or change in vision. He has no new lump, skin change, or swelling on either side of the chest or in either armpit, and no bone pain, cough, or weight loss. He walks most days and keeps a busy schedule of writing and speaking, including talking to men about breast cancer. He has had no falls, emergency visits, or hospital stays since his operation. [S]
| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit |
| Safety events | No falls, emergency visits, or hospital stays since his operation |
| Medicines | Tamoxifen 20 mg daily; cholecalciferol 1000 units daily; no other prescription or over-the-counter medicines |
| Active conditions | Right breast cancer, stage IIA, on adjuvant tamoxifen, no evidence of recurrence; low bone mass at the femoral neck |
| Functional status | Independent in all activities and instrumental activities of daily living |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good |
| Psychosocial | Busy with writing, board work, and speaking; close family and friends; no loneliness or low mood |
| Tobacco | Never used tobacco |
| Alcohol and drugs | Does not drink alcohol (AUDIT-C 0); no other drug use |
| Physical activity | Walks 30 to 40 minutes most days and does light weights twice a week |
| Nutrition | Regular balanced meals; dairy twice a day for calcium |
| Sleep | Seven hours a night; hot flashes wake him about once a week |
| Activities of daily living | Independent |
| Instrumental activities of daily living | Independent; manages his own medicines with a weekly pill organizer; drives |
| Home safety | Smoke detectors working; handrails on the stairs; good lighting |
| Falls | No falls this year; no fear of falling |
| Hearing and vision | No hearing concern; wears reading glasses; eye examination eight months ago |
| Memory | No concerns |
| Pain | None |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; no fatigue, fever, or night sweats |
| Eyes | Negative | No change in vision on tamoxifen |
| Ears, nose, mouth, and throat | Negative | No hearing loss or mouth problems |
| Cardiovascular | Negative | No chest pain, palpitations, or leg swelling or pain |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No change in bowel habit or bleeding |
| Genitourinary | Positive | Lower libido on tamoxifen, not bothersome; no urinary symptoms or blood in the urine |
| Musculoskeletal | Negative | No bone or joint pain; full shoulder movement |
| Integumentary | Negative | No new lump or skin change on the chest wall; no new skin lesions |
| Neurological | Negative | No headache, weakness, or numbness |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
| Endocrine | Positive | Mild hot flashes two or three times a week on tamoxifen |
| Hematologic and lymphatic | Negative | No arm swelling, easy bruising, or enlarged glands |
13 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) | One tablet once daily | Oral route | 2025-10-28 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-02-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-13 | Body height | 183 | cm | S |
| 2026-10-13 | Body weight | 82.4 | kg | S |
| 2026-10-13 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 2026-10-13 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-10-13 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-13 | Heart rate | 68 | /min | S |
| 2026-10-13 | Respiratory rate | 14 | /min | S |
| 2026-10-13 | Body temperature | 36.6 | Cel | S |
| 2026-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-13 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-10-13 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2026-10-13 | Cholesterol [Mass/volume] in Serum or Plasma | 176 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-10-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-10-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 104 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-10-13 | Triglyceride [Mass/volume] in Serum or Plasma | 92 | mg/dL | <=149 mg/dL | Normal | S |
Vital signs recorded on 2026-10-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well, alert, and upright; weight 82.4 kg, BMI 24.6 |
| Eyes | Pupils equal and reactive; near vision 20/30 with reading glasses |
| Ears | Canals clear; whispered-voice test passed in both ears |
| Neck | No thyroid enlargement; no cervical or supraclavicular nodes |
| Chest wall | Healed transverse mastectomy scars on both sides; no nodule, thickening, or skin change on either side |
| Lymph nodes | No axillary nodes on either side; right axillary scar healed |
| Cardiovascular | Regular rhythm at 68 per minute; no murmur; no calf tenderness or swelling; arm circumferences equal |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft and non-tender; liver not enlarged |
| Musculoskeletal | No spinal tenderness; Timed Up and Go 10 seconds; rises from a chair without using his arms |
| Neurological | Alert and oriented; gait steady; Mini-Cog 5 of 5 |
| Psychiatric | Euthymic and engaged; judgment and insight intact |
| Skin | No suspicious lesions |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast cancer | active | confirmed | C50.121 | S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D). |
| Estrogen receptor-positive status of the breast cancer | active | confirmed | Z17.0 | S — Synthetic receptor result; his tumor biology was not made public. |
| Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health review | active | confirmed | Z79.810 | S — Synthetic adjuvant therapy in the modern episode. |
| Absence of both breasts after bilateral mastectomy | active | confirmed | Z90.13 | S — The double mastectomy is reported publicly (D); the coding is synthetic. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, this season | Completed today | High-dose vaccine given today |
| Pneumococcal vaccine | Completed today | PCV20 given today; no earlier pneumococcal vaccine on record; no further doses needed |
| Recombinant zoster vaccine | Completed today | Dose 1 given today; dose 2 due in two to six months |
| RSV vaccine | Due | A single dose is recommended at 75 and older; he will get it at the pharmacy with his COVID-19 dose |
| COVID-19 vaccine, this season | Due | Recommended at his age; at the pharmacy next week |
| Tetanus, diphtheria, and pertussis booster | Up to date | Tdap eight years ago; next dose due in two years |
| Colorectal cancer screening | Not indicated | Screening from 76 to 85 is selective; discussed, and not recommended for him now, given his age and his current cancer care |
| Prostate cancer screening | Not indicated | PSA screening is not recommended at 70 and older; his germline panel showed no BRCA2 or other variant that would change this |
| Breast imaging | Not indicated | After bilateral mastectomy there is no breast to image; surveillance is by examination of both sides of the chest wall |
| Bone density | Up to date | DXA eight months ago: femoral neck T-score -1.2, spine -0.4; vitamin D now 36 ng/mL; repeat in two years |
| Cholesterol and statin decision | Completed today | Total cholesterol 176, HDL 54, LDL 104 mg/dL; no diabetes or smoking. Risk calculators are not validated beyond 79, and evidence for starting a statin for primary prevention after 75 is limited; not started after discussion; review yearly |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | Never used tobacco |
| Hepatitis C and HIV screening | Not indicated | Outside the recommended age ranges and no risk factors |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 0 |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | Timed Up and Go 10 seconds; no falls; walking and light weights continue |
| Hearing | Completed today | Whispered-voice test passed in both ears |
| Eye examination | Up to date | Eight months ago; tamoxifen can rarely cause cataract or retinal changes, so he will report any change in vision |
Immunizations given today: High-dose influenza vaccine, 2026-2027 season; Pneumococcal conjugate vaccine PCV20; Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Survivorship visit in two months. Second zoster dose in two to six months. COVID-19 and RSV vaccines at the pharmacy. Next annual wellness visit in one year. [S]
Voluntary advance care planning discussion of about 20 minutes, with his consent. He named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is staying active in his work, being told plainly about his health, and making his own decisions. He chose not to record specific treatment preferences today. The plan will be revisited yearly and with any change in his health. [S]